High-flow oxygen therapy for treatment of acute migraine: A randomized crossover trial. (July 2017)

• Record Type: Journal Article
• Authors: Singhal, Aneesh B; Maas, Matthew B; Goldstein, Joshua N; Mills, Brittany B; Chen, David W; Ayata, Cenk; Kacmarek, Robert M; Topcuoglu, Mehmet A
• Is Part Of: Cephalalgia. Volume 37:Number 8(2017)
• Page Start: 730
• Page End: 736
• Publication Date: 2017-07
• Subjects: Migraine -- normobaric oxygen therapy -- headache; Headache -- Periodicals; 616.8491
• DOI: 10.1177/0333102416651453
• Languages: English
• ISSNs: 0333-1024

Abstract

Background: Impaired oxygen utilization and cerebrovascular dysfunction are implicated in migraine. High-flow oxygen is effective in cluster headache and has shown promise in animal models of migraine, but has not been adequately studied in patients with migraine. Methods: In this randomized, crossover-design, placebo-controlled trial, adult migraineurs self-administered high-flow oxygen or medical air at 10–15 l/min via face mask in blinded fashion starting soon after symptom onset for 30 minutes, for a total of four migraine attacks. Participants recorded the severity of headache, nausea, and visual symptoms on visual analog scales periodically up to 60 minutes. Results: We enrolled 22 individuals (mean age 36 years, 20 women) who self-treated 64 migraine attacks (33 oxygen, 31 air). The pre-specified primary endpoint (mean decrease in pain score from baseline to 30 minutes) was 1.38 ± 1.42 in oxygen-treated and 1.22 ± 1.61 in air-treated attacks ( p = 0.674). Oxygen therapy resulted in relief (severity score 0–1) of pain (24% versus 6%, p = 0.05), nausea (42% versus 23%, p = 0.08) and visual symptoms (36% versus 7%, p = 0.004) at 60 minutes. Exploratory analysis showed that in moderately severe attacks (baseline pain score <6), pain relief was achieved in six of 13 (46%) oxygen versus one of 15 (7%) air ( p = 0.02). Gas therapy was used per protocol in 91% of attacks. There were no significant adverse events. Conclusion: High-flow oxygen may be a feasible and safe strategy to treat acute migraine. Further studies are required to determine if this relatively inexpensive, widely available treatment can be used as an adjunct or alternative migraine therapy.